treated 60 non‐squamous NSCLC patients harboring sensitizing EGFR mutations with the ABCP regimen after frontline EGFR‐TKI, resulting in a median PFS of 7.4 months and an OS of 23.1 months in the cohort [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.